It's A List! Why Is China's Rare Disease List A Major Milestone For Orphan Drug Developers?
Largely different from the US and EU, China is tackling rare diseases with a first-ever official list of 121 conditions for now, which could be a major milestone for orphan drug developers, some experts say.
You may also be interested in...
The Pink Sheet's pick of eight major events that captured major regulatory developments in China’s dynamic, highly fluid biopharma scene in 2018.
China officially issues regulation accepting clinical data obtained from overseas studies, with a priority on treatments for critical, rare and pediatric conditions.